STOCK TITAN

TG Therapeutics, Inc. - TGTX STOCK NEWS

Welcome to our dedicated page for TG Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on TG Therapeutics stock.

TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company headquartered in New York City, dedicated to developing and commercializing innovative treatments for B-cell malignancies and autoimmune diseases. The company has a rich pipeline of products aimed at addressing unmet medical needs in these areas.

One of TG Therapeutics' flagship products is BRIUMVI® (ublituximab-xiiy), a novel monoclonal antibody targeting CD20-expressing B-cells. BRIUMVI is FDA-approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company has also received approval from the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of RMS in Europe and the United Kingdom, respectively.

In addition to BRIUMVI, TG Therapeutics is advancing several other therapies:

  • TG-1701 (BTK inhibitor)
  • TG-1801 (anti-CD47/CD19 bispecific mAb)
, targeting B-cell disorders in Phase 1 trials. The company is also working on TG-1101 (ublituximab) and TGR-1202 (umbralisib), both in clinical development for hematologic malignancies.

Recent company news highlights the robust clinical activity of BRIUMVI, as demonstrated in the ULTIMATE I & II Phase 3 trials, and the company’s ongoing commitment to the multiple sclerosis community. TG Therapeutics has also been awarded a national contract with the Department of Veterans Affairs (VA) to list BRIUMVI as the preferred agent on the VA National Formulary for Anti-CD20 Antibody indications.

Financially, TG Therapeutics reported strong first-quarter 2024 sales, with BRIUMVI U.S. net revenue exceeding $50 million, leading to revised annual guidance of $270 to $290 million for 2024. The company is focused on expanding its commercial infrastructure and advancing its research pipeline, including developing a subcutaneous form of BRIUMVI and moving the therapy into additional indications beyond MS.

For more information, visit the company’s website at www.tgtherapeutics.com.

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) presented promising data at the 25th European Hematology Association annual congress. Key highlights include ongoing favorable results for TG-1701, a selective BTK inhibitor in various B-cell malignancies, showing a 92% overall response rate in CLL patients. The combination therapy of umbralisib and ibrutinib also exhibited a 95% response rate for CLL with no delayed toxicities, emphasizing the potential for effective dual-targeted treatment approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
-
Rhea-AI Summary

TG Therapeutics, Inc. (NASDAQ: TGTX) announced that CEO Michael S. Weiss will participate in a fireside chat at the Goldman Sachs 41st Annual Healthcare Conference on June 11, 2020, at 4:40 PM ET. A live webcast will be available on the company's website. TG Therapeutics focuses on developing novel treatments for B-cell malignancies and autoimmune diseases, with therapies such as ublituximab and umbralisib in Phase 3 clinical development. The company is headquartered in New York City.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
conferences
-
Rhea-AI Summary

TG Therapeutics, Inc. (NASDAQ: TGTX) announced that its Executive Chairman and CEO, Michael S. Weiss, will participate in a fireside chat at the Jefferies 2020 Healthcare Conference on June 3, 2020, at 10:00 AM ET. This event will be virtual, and a live webcast can be accessed on the Company’s Investors & Media page. TG Therapeutics focuses on developing therapies for B-cell malignancies and autoimmune diseases, including the Phase 3 clinical development of ublituximab and umbralisib.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences
Rhea-AI Summary

TG Therapeutics has announced favorable final results from its GENUINE Phase 3 study, which evaluated the impact of adding ublituximab to ibrutinib in patients with high-risk chronic lymphocytic leukemia (CLL). The combination significantly improved progression-free survival (PFS), overall response rate (ORR), and rates of undetectable minimal residual disease (uMRD) compared to ibrutinib alone. Specifically, ORR was 93% for the combination versus 78% for monotherapy. This study suggests a promising potential for ublituximab combined with ibrutinib in managing high-risk CLL.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.52%
Tags
-
Rhea-AI Summary

On May 15, 2020, TG Therapeutics (NASDAQ: TGTX) announced that preclinical data for TG-1701, a selective BTK inhibitor, will be presented at the 2020 American Association for Cancer Research (AACR) annual meeting. The presentation, titled 'TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro,' will be available on demand starting June 22, 2020. TG Therapeutics is advancing multiple therapies for B-cell malignancies and autoimmune diseases and is currently in various clinical development phases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences clinical trial
-
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) announced a $153 million public offering of 8,500,000 shares at $18.00 each, upsized from an initial estimate of 6 million shares. The offering is expected to close on May 19, 2020, pending standard conditions. Proceeds will support the development of ublituximab and umbralisib, possible acquisitions, and general corporate needs. The underwriters have a 30-day option for an additional 1,275,000 shares. Major financial institutions are managing the offering, which utilizes an effective shelf registration filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
Rhea-AI Summary

TG Therapeutics (TGTX) announced plans to offer 6,000,000 shares of common stock in an underwritten public offering, subject to market conditions. The underwriters may purchase an additional 15% of the shares. Proceeds will fund the development of ublituximab and umbralisib, alongside potential acquisitions and general corporate needs. The offering is made under an effective shelf registration statement filed with the SEC. J.P. Morgan, Jefferies, Evercore, and Cantor Fitzgerald are managing the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
-
Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) announced data presentations scheduled for the ASCO and EHA annual meetings in May and June 2020. The company will present results from three combination trials, highlighting the GENUINE Phase 3 trial's final results that show a PFS benefit for ublituximab in high-risk CLL patients compared to ibrutinib alone. Additionally, long-term results from umbralisib and ibrutinib combinations will be discussed. The presentations emphasize the ongoing development of TGTX's novel therapies targeting B-cell malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
none
-
Rhea-AI Summary

TG Therapeutics, Inc. (NASDAQ: TGTX) reported a net loss of $51.1 million for Q1 2020, up from $35.2 million in Q1 2019. The company is buoyed by positive topline results from its UNITY-CLL Phase 3 trial and a strong cash position of approximately $154.3 million post-ATM facility utilization. Key milestones include the NDA submission for umbralisib in marginal zone lymphoma (MZL) and follicular lymphoma (FL) and the anticipated release of pivotal trial data in 2020. Despite increased R&D costs of $34 million, the company remains optimistic about future cash sufficiency through 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags

FAQ

What is the current stock price of TG Therapeutics (TGTX)?

The current stock price of TG Therapeutics (TGTX) is $25.06 as of October 31, 2024.

What is the market cap of TG Therapeutics (TGTX)?

The market cap of TG Therapeutics (TGTX) is approximately 3.4B.

What is TG Therapeutics' primary focus?

TG Therapeutics focuses on developing and commercializing treatments for B-cell malignancies and autoimmune diseases.

What is BRIUMVI?

BRIUMVI (ublituximab-xiiy) is a monoclonal antibody targeting CD20-expressing B-cells, approved for treating relapsing forms of multiple sclerosis (RMS).

Where is TG Therapeutics headquartered?

The company is headquartered in New York City.

What recent financial performance did TG Therapeutics report?

The company reported over $50 million in BRIUMVI U.S. net revenue for Q1 2024 and updated its annual guidance to $270 to $290 million.

Has BRIUMVI received regulatory approvals outside the U.S.?

Yes, BRIUMVI has been approved by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for RMS treatment in Europe and the UK.

What other therapies is TG Therapeutics developing?

TG Therapeutics is also developing TG-1701, TG-1801, TG-1101 (ublituximab), and TGR-1202 (umbralisib) for B-cell disorders and hematological malignancies.

What are the ULTIMATE I & II Phase 3 trials?

The ULTIMATE I & II trials are clinical studies evaluating the efficacy of BRIUMVI in treating relapsing forms of multiple sclerosis.

What support programs does TG Therapeutics offer for BRIUMVI?

TG Therapeutics offers BRIUMVI Patient Support, a flexible program designed to assist U.S. patients through their treatment journey.

What is the significance of TG Therapeutics' national contract with the VA?

The contract makes BRIUMVI the preferred anti-CD20 antibody therapy for RMS on the VA National Formulary, enhancing access for veterans.

Where can more information about TG Therapeutics be found?

More information is available on the company's website at www.tgtherapeutics.com.

TG Therapeutics, Inc.

Nasdaq:TGTX

TGTX Rankings

TGTX Stock Data

3.40B
154.82M
9.59%
61.21%
20.98%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK